| Drug Name |
Cefixime |
| Drug ID |
BADD_D00388 |
| Description |
Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall. |
| Indications and Usage |
For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis, (2) otitis media caused by Haemophilus influenzae (beta-lactamase positive and negative strains), Moraxella catarrhalis (most of which are beta-lactamase positive), and S. pyogenes, (3) pharyngitis and tonsillitis caused by S. pyogenes, (4) acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase positive and negative strains), and (5) uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains). |
| Marketing Status |
approved; investigational |
| ATC Code |
J01DD08 |
| DrugBank ID |
DB00671
|
| KEGG ID |
D00258; D07640
|
| MeSH ID |
D020682
|
| PubChem ID |
5362065
|
| TTD Drug ID |
D06OVY
|
| NDC Product Code |
82608-007; 67877-584; 68180-423; 83112-584; 27437-201; 27437-203; 27437-208; 62250-663; 62250-668; 68180-405; 65862-791; 27437-205; 27437-207; 16714-767; 27437-206; 70518-3221; 43598-673; 68180-202; 62250-664; 65862-751; 68180-407; 61788-3000; 16714-766; 43598-674; 65862-752; 70518-2749 |
| UNII |
97I1C92E55
|
| Synonyms |
Cefixime | Suprax | Cefixime Anhydrous | Cefixime Trihydrate | FK-027 | FK027 | FK 027 | FR-17027 | FR 17027 | FR17027 |
